A Study With RO4917523 in Patients With Fragile X Syndrome

Summary

This randomized, double-blind multiple ascending dose study will evaluate the safety and tolerability, pharmacokinetics and efficacy of RO4917523 in patients with Fragile X Syndrome. The patients will be randomized to receive either active drug or placebo. The anticipated time on study treatment is 6 weeks. The target sample size is \<100 patients.

Timeline

Start

2009-11

Primary completion

2011-01

Completion

2011-01

Drugs

Indications